Tirzepatide for Smoking Cessation

This trial tests a medication called tirzepatide to determine its effectiveness in helping people quit smoking and manage weight gain after quitting. Participants will use either tirzepatide or a placebo, along with nicotine patches, for 16 weeks. The trial seeks individuals who have smoked at least 10 cigarettes a day for over two years and have a body mass index (BMI) of 25 or higher. This study may suit those serious about quitting smoking soon and open to weekly clinic visits. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you stop taking certain medications, such as other weight loss, diabetes, or smoking cessation medications (except nicotine patches) and psychiatric medications if they were started or changed in the past 30 days. If you're on opioid replacement therapy, you can continue if you provide documentation.

Research shows that tirzepatide, a drug tested to help people quit smoking, has also been studied for weight loss and diabetes. This research provides insight into its safety. While safety information is still being gathered, studies have reported some side effects. These may include nausea, diarrhea, and reduced appetite, but they are usually mild and temporary.

Tirzepatide is unique because it's being explored for smoking cessation, an area where traditional options like nicotine replacement therapies and medications such as varenicline and bupropion are typically used. Most treatments for smoking cessation focus on reducing nicotine cravings or blocking its effects. However, Tirzepatide, originally developed for diabetes, works by mimicking hormones that regulate appetite and blood sugar, potentially addressing smoking-related cravings differently. This novel approach could offer a fresh angle in helping people quit smoking, which has researchers intrigued about its potential effectiveness.

Research has shown that tirzepatide, a medication with dual actions, might help people quit smoking by reducing nicotine cravings. This trial will compare tirzepatide to a placebo to assess its effectiveness in smoking cessation. Studies have found that medications affecting GLP-1 receptors, which play a role in hunger and cravings, can decrease both nicotine and food cravings. Tirzepatide is already known to aid in weight loss and blood sugar control, potentially helping people avoid weight gain after quitting smoking. Early evidence suggests that because tirzepatide targets two receptors instead of just one, it might be more effective than other similar treatments. However, further research is needed to fully understand its impact on smoking cessation.¹³⁶⁷⁸